-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF FEBRUARY 2, 2025 – FEBRUARY 08, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Data Release 02/03/2025 IVVD 55.1 44 0.36 Conference 02/05/2025 ANAB 30.6 2,770 17.93 Conference 02/05/2025 CABA 22.5 12,509 2.39 Conference 02/05/2025 ABSI 23.2 14,305 3.71 Conference 02/06/2025 PRAX 33.6 13,932 76.55 Conference 02/06/2025 FBRX 23.4 504 15.89 Conference 02/06/2025 ADCT 32.3 172 1.68…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF JANUARY 26, 2025 – FEBRUARY 01, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ Conference 01/28/2025 LXRX 49.9 4,606 0.99 Conference 01/28/2025 IPA 28.7 3,588 0.58 Webinar 01/29/2025 OTLK 21.0 1,839 1.99 Corporate Event 01/29/2025 ZNTL 58.3 4,312 2.22 FDA Event 01/30/2025 VRTX 17.34 48,375 439.62 FDA Event 01/31/2025 AXSM 13.99 45,376 103.11 Clinical Trial 02/01/2025 SUPN…
-
BIO-TECH STOCK CATALYST REPORT FOR WEEK OF DECEMBER 29, 2024 – JANUARY 04, 2025
EVENT EVENT DATE SYMBOL PRICE POTENTIAL % (+/-) OPEN INTEREST PRICE $ FDA Event 12/29/2024 NBIX 4.2 1,817 139.44 FDA Event 12/29/2024 BMY 2.5 5,932 57.68 Clinical Trial 12/30/2024 BCLI 42.3 782 2.45 FDA Event 12/30/2024 NBIX 4.2 1,817 139.44 Clinical Trial 12/31/2024 ALDX 13.0 6,889 4.94 Clinical Trial 12/31/2024 ABBV 2.1 6,221 178.01 Clinical…
-
Clover Health to Participate in Upcoming 43rd Annual J.P. Morgan Healthcare Conference
Clover Health’s upcoming participation in the 43rd Annual J.P. Morgan Healthcare Conference holds significant promise for the healthcare industry and market observers alike. As a key player in the healthcare sector, Clover Health’s involvement in this prestigious event underscores its commitment to innovation, growth, and industry leadership. This article delves into the details of Clover…
-
IDEAYA Biosciences Enters Exclusive License with Hengrui Pharma for SHR-4849, a Novel Phase 1 DLL3 Topo-I-Payload ADC Targeting SCLC and NET Solid Tumors
NASDAQ: IDYA IDEAYA Biosciences’ recent exclusive license agreement with Hengrui Pharma for SHR-4849 marks a significant milestone in the field of oncology therapeutics. This partnership brings forth a promising novel Phase 1 DLL3 Topo-I-Payload Antibody-Drug Conjugate (ADC) targeting Small Cell Lung Cancer (SCLC) and Neuroendocrine Tumors (NET). The collaboration between these two renowned pharmaceutical companies…
-
Presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial highlighting new findings from the ATTENTION-AD study evaluating potential benefit of oral once daily blarcamesine (ANAVEX®2-73) in early Alzheimer’s disease.
NASDAQ: AVXL The presentation of topline long-term data from the Phase IIb/III ATTENTION-AD Open-Label-Extension (OLE) trial marks a significant milestone in the field of Alzheimer’s disease research. This article delves into the latest findings from the ATTENTION-AD trial, shedding light on the efficacy and safety of the investigational treatment over an extended period. With a…